Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE 2, and MMP-13 expression

Acta Pharmacologica Sinica

Volumn 34, Issue 3, 2013, Pages 403-413

  Wei, Zhi Feng ^a   Jiao, Xiao Lan ^a   Wang, Ting ^a   Lu, Qian ^a   Xia, Yu Feng ^a   Wang, Zheng Tao ^b   Guo, Qing Long ^a   Chou, Gui Xin ^b   Dai, Yue ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

adjuvant induced arthritis; COX 2; dexamethasone; fibroblast like synoviocyte; IL 6; joint destruction; MMP 13; norisoboldine; p38 ERK AKT AP 1 pathway; PGE2; receptor activator of nuclear factor B ligand; rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; COLLAGENASE 3; CYCLOOXYGENASE 2; DEXAMETHASONE; FREUND ADJUVANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; ISOQUINOLINE ALKALOID; NORISOBOLDINE; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CARTILAGE; HISTOLOGY; INFLAMMATORY CELL; JOINT DESTRUCTION; MALE; MYCOBACTERIUM BUTYRICUM; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RADIOGRAPHY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWELLING; SYNOVIOCYTE; SYNOVITIS; TREATMENT DURATION;

ALKALOIDS; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHROGRAPHY; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERLEUKIN-6; JOINTS; MALE; MATRIX METALLOPROTEINASE 13; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; SYNOVIAL MEMBRANE;

EID: 84874644568     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.187     Document Type: Article

References (48)

1. Ngian GS. Rheumatoid arthritis. Aus Fam Physician 2010; 39: 626-8.
2. Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am 2010; 36: 385-404.
3. Goldring SR. Bone and joint destruction in rheumatoid arthritis: what is really happening? J Rheumatol 2002; 65: 44-8.
4. Carmona L, Cross M, Williams B, Lassere M, March L. Rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010; 24: 733-45.
5. Yang CL, Or TC, Ho MH, Lau AS. Scientific basis of botanical medicine as alternative remedies for rheumatoid arthritis. Clin Rev Allergy Immunol 2012. doi: 10.1007/s12016-012-8329-8.
6. Zhao J, Zha Q, Jiang M, Cao H, Lu A. Expert consensus on the treatment of rheumatoid arthritis with Chinese patent medicines. J Altern Complement Med 2012. doi: 10.1089/acm.2011.0370.
7. Zhao XX, Peng C, Zhang H, Qin LP. Sinomenium acutum: A review of chemistry, pharmacology, pharmacokinetics, and clinical use. Pharm Biol 2012; 50: 1053-61.
8. Wang C, Dai Y, Yang J, Chou G, Wang C, Wang Z. Treatment with total alkaloids from Radix Linderae reduces in ammation and joint destruction in type II collagen-induced model for rheumatoid arthritis. J Ethnopharmacol 2007; 111: 322-8.
9. Luo Y, Liu M, Dai Y, Yao X, Xia Y, Chou G, et al. Norisoboldine inhibits the production of pro-inflammatory cytokines in lipopolysaccharidestimulated RAW 264.7 cells by down-regulating the activation of MAPKs but not NF-κB. Inflammation 2010; 33: 389-97.
10. Wei Z, Wang F, Song J, Lu Q, Zhao P, Xia Y, et al. Norisoboldine inhibits the production of interleukin-6 in fibroblast-like synoviocytes from adjuvant arthritis rats through PKC/MAPK/NF-κB-p65/CREB pathways. J Cell Biochem 2012; 113: 2785-95.
11. Chou GX, Norio N, Ma CM, Wang ZT, Masao H. Isoquinoline alkaloids from Lindera aggregata. Chin J Nat Med 2005; 5: 272-5.
12. Jawed H, Shah SU, Jamall S, Simjee SU. N-(2-hydroxy phenyl) acetamide inhibits inflammation-related cytokines and ROS in adjuvantinduced arthritic (AIA) rats. Int Immunopharmacol 2010; 10: 900-5.
13. Yifan W, Dengming W, Zheng L, Yanping L, Junkan S. Triptolide inhibits CCR5 expressed in synovial tissue of rat adjuvant-induced arthritis. Pharmacol Rep 2007; 59: 795-9.
14. Nagai N, Fukuhata T, Ito Y, Usui S, Hirano K. Preventive effect of coadministration of water containing magnesium ion on indomethacin induced lesions of gastric mucosa in adjuvant-induced arthritis rat. Biol Pharm Bull 2009; 32: 116-20.
15. Zhu L, Wei W, Zheng YQ, Jia XY. Effects and mechanisms of total glucosides of paeony on joint damage in rat collagen-induced arthritis. Inflamm Res 2005; 54: 211-20.
16. Wang QT, Zhang LL, Wu HX, Wei W. The expression change of β-arrestins in ?broblast-like synoviocytes from rats. J Ethnopharmacol 2011; 133: 511-6.
17. Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 1068-76.
18. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts Arthritis Res Ther 2007; 9: 203.
19. Huh JE, Hong JM, Baek YH, Lee JD, Choi DY, Park DS. Antiinflammatory and anti-nociceptive effect of Betula platyphylla var. japonica in human interleukin-1β-stimulated fibroblast-like synoviocytes and in experimental animal models. J Ethnopharmacol 2011; 135: 126-34.
20. Giuliani N, Morandi F, Tagliaferri S, Rizzoli V. Targeting pathways mediating bone disease. Curr Pharm Biotechnol 2006; 7: 423-9.
21. Blair JM, Zheng Y, Dunstan CR. RANK ligand. Int J Biochem Cell Biol 2006; 39: 1077-81.
22. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 233-55.
23. Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 2-9.
24. Rossa C, Ehmann K, Liu M, Patil C, Kirkwood KL. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells. J Interferon Cytokine Res 2006; 26: 719-29.
25. Tang ZN, Zhang F, Tang P, Qi XW, Jiang J. Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells. Biochem Biophys Res Commun 2011; 408: 411-6.
26. Wang JH, Shih KS, Liou JP, Wu YW, Chang AS, Wang KL, et al. Antiarthritic effects of magnolol in human interleukin 1β-stimulated fibroblast-like synoviocytes and in a rat arthritis model. PLoS One 2012; 7: e31368.
27. Teramachi J, Kukita A, Li YJ, Ushijima Y, Ohkuma H, Wada N, et al. Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis. Lab Invest 2011; 91: 719-31.
28. Lubahn C, Schaller JA, Shewmacker E, Wood C, Bellinger DL, Byron D, et al. Preclinical efficacy of sodium narcistatin to reduce inflammation and joint destruction in rats with adjuvant-induced arthritis. Rheumatol Int 2012; 32: 3751-60.
29. Cuzzocrea S, Mazzon E, Paola RD, Genovese T, Muià C, Caputi AP, et al. Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis. Arthritis Rheum 2005; 52: 1929-40.
30. Islander U, Jochems C, Stubelius A, Andersson A, Lagerquist MK, Ohlsson C, et al. Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis. Arthritis Res Ther 2011; 13: R96.
31. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002; 61: ii84-6.
32. Okamoto K, Takayanagi H. Osteoclasts in arthritis and Th17 cell development. Int Immunopharmacol 2011; 11: 543-8.
33. Broadhead ML, Clark JC, Dass CR, Choong PF, Myers DE. Therapeutic targeting of osteoclast function and pathways. Expert Opin Ther Targets 2011; 15: 169-81.
34. Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res 2008; 68: 5803-11.
35. Blair HC, Zaidi M. Osteoclastic differentiation and function regulated by old and new pathways. Rev Endocr Metab Disord 2006; 7: 23-32.
36. Lewiecki EM. Denosumab for joints and bones. Curr Rheumatol Rep 2009; 11: 196-201.
37. Sharp JT, Tsuji W, Ory P, Harper-Barek C, Wang H, Newmark R. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62: 537-44.
38. Neumann E, Gay S, Müller-Ladner U. The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. Arthritis Rheum 2005; 52: 2960-7.
39. Ha MK, Song YH, Jeong SJ, Lee HJ, Jung JH, Kim B, et al. Emodin inhibits proinflammator y responses and inactivates histone deacetylase 1 in hypoxic rheumatoid synoviocytes. Biol Pharm Bull 2011; 34: 1432-7.
40. Chang Y, Wei W, Zhang L, Xu HM. Effects and mechanisms of total glucosides of paeony on synoviocytes activities in rat collagen-induced arthritis. J Ethnopharmacol 2009; 121: 43-8.
41. Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D, et al. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 2002; 46: 1789-803.
42. Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis 2011; 2011: 765624.
43. Ryu JH, Yang S, Shin Y, Rhee J, Chun CH, Chun JS. Interleukin-6 plays an essential role in hypoxia-inducible factor 2α-induced experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum 2011; 63: 2732-43.
44. Shiozawa S, Tsumiyama K. Pathogenesis of rheumatoid arthritis and c-Fos/AP-1. Cell Cycle 2009; 8: 1539-43.
45. Handel ML, Girgis L. Transcription factors. Best Pract Res Clin Rheumatol 2001; 15: 657-75.
46. Yamanishi Y, Firestein GS. Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum Dis Clin North Am 2001; 27: 355-71.
47. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001; 108: 73-81.
48. Hazeki K, Nigorikawa K, Hazeki O. Role of phosphoinositide 3-kinase in innate immunity. Biol Pharm Bull 2007; 30: 1617-23.